ClinicalTrials.gg
RecruitingNCT03774420Updated Oct 16, 2026

Post Operative Cognitive Dysfunction After Oncologic Surgery

An observational study in Emergence Delirium and Post-Operative Cognitive Dysfunction, sponsored by University of Padova. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by University of Padova · Observational

How we know

From the registry’s dates

  • Started Jul 2019; still recruiting 7 years 4 months later.
Updated Oct 16, 2026Eligibility revisedPrimary outcomes revised+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Emergence Delirium with a site in Italy — 5 open to participants now, 5 under way, none of them phase 3. Emergence Delirium · Italy.

Started
2019
with 1 other
Observational
7 of 13
2 open now
Registered
5th of 13
by date
Lead sponsor
2 of 13
University of Padova

Among the 13 studies in Emergence Delirium with a site in Italy, this one is one of 2 that started in 2019, is one of 7 observational ones, and was the 5th registered.

Emergence Delirium

753 studies on the registry are indexed under Emergence Delirium; 261 are open to participants now.

Browse Emergence Delirium studies →

Open to participants now

5 of the 13 studies in Emergence Delirium with a site in Italy are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 141 Emergence Delirium studies recruiting now, 78 (55%) set no upper age limit and 43 (30%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Emergence Delirium with a site in Italy, or all of them as a file.
02

Study summary

Aim of this trial is to define if Post-Operative Cognitive Dysfunction, detected analyzing changes between pre-operative and post-operative Neurocognitive Test, and Postoperative Delirium, relate to concentration of effector's site concentration of propofol and remifentanil TCI and to the common intraoperative neuromonitoring values as well as to Pupillometry values (in particular Pupil Diameter, Pupil Latency, and Maximum Contraction Velocity).

Read the detailed description

Post-Operative Cognitive Dysfunction has not been yet investigated after general anaesthesia with Targeted-Controlled-Infusion (TCI) and Laryngeal-Mask-Airway (LMA), daily used in the investigator's Hospital to anesthetize patients undergoing oncologic surgery (breast, urologic and general surgery). Aim of this trial is to define if neurocognitive tests (Montreal Cognitive Assessment, Trail Making Test A and B, Digit Span Test) before and after surgery, and CAM for Postoperative Delirium relate to concentrations at effector's site (Ce) of propofol and remifentanil TCI and the values of Bispectral Index and Entropy monitoring and Surgical Plethysmographic Index (SPI), as well as to Pupillometry values.

03

Conditions studied

  • Emergence Delirium
  • Post-Operative Cognitive Dysfunction

Browse trials for

Keywords

  • Infusion pumps
  • Intraoperative brain monitoring
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Women and Men subjected to oncologic surgery (breast, urologic general surgery) in general anaesthesia with Laryngeal-Mask-Airway (LMA) anesthetized with propofol and remifentanil delivered by Targeted-Controlled-Infusion (TCI) pumps. Patients will be subjected to neurocognitive tests (MMSE, GEMS, TMT A and B) the day before surgery and before hospital discharge. These test will be related to propofol and remifentanil concentrations at effector site during surgery and awakening, to BIS and Entropia values and to SPI and pupillometry values.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • General Anaesthesia delivered with Propofol and Remifentanil with Targeted Controlled Infusion
  • Use of Laryngeal Mask airway

Exclusion criteria

Exclusion Criteria:

  • Neurological pathologies
  • Haemodynamical instability during surgery
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Incidence of Post-Operative Cognitive Dysfunction in oncologic surgery (breast, urolgic and general surgery) patients detected with Global Examination of Mental Test (GEMS)

    Discover incidence of Post-Operative Cognitive decline analyzing changes in Post-Operative Cognitive Dysfunction changes between Pre-operative Global Examination of Mental Test (GEMS) test. Better neurocognitve outcome with higher scores)

    Time frame: Patients will be subjected to Global Examination of Mental Test (GEMS) test one day before surgery and 1 day after surgery.

  2. Incidence of Post-Operative Cognitive Dysfunction in oncologic surgery (breast, urolgic and general surgery) patients detected with Minimental State Examination (MMSE)

    Discover incidence of Post-Operative Cognitive decline analyzing changes in Post-Operative Cognitive Dysfunction changes between Pre-operativeMinimental State Examination (MMSE) test. Better neurocognitve outcome with higher scores)

    Time frame: Patients will be subjected to Minimental State Examination (MMSE) test one day before surgery and 1 day after surgery.

  3. Incidence of Post-Operative Cognitive Dysfunction in oncologic surgery (breast, urolgic and general surgery) patients detected with Trail Making Test A and B

    Discover Post-Operative Cognitive Dysfunction analyzing changes between Pre-operative Trail Making Test A and B test score and post-operative Trail Making Test A and B test score. These tests will be evaluated in seconds required to be completed (better neurocognitive outcome with fewer seconds required)

    Time frame: Patients will be subjected to Trail Making Test (TMT) A and B one day before surgery and 1day after surgery.

  4. Incidence of Post-Operative Delirium in oncologic surgery (breast, urolgic and general surgery) patients

    Discover Post-Operative Delirium submitting patients Confusion Assessment Method (CAM) test. Worse neurocognitve outcome with higher scores (ranging from 0 to 4)

    Time frame: Patients will be subjected to Confusion Assessment Method (CAM) within 1 hour from awakening from anesthesia .

  5. Incidence of Post-Operative Cognitive Dysfunction in oncologic surgery (breast, urolgic and general surgery) patients

    Discover Post-Operative Cognitive Dysfunction analyzing changes between Pre-operative Short Portable Mental Status Questionnaire score and post-operative Short Portable Mental Status Questionnaire test score. Better neurocognitve outcome with higher scores (ranging 0 to 10)

    Time frame: Patients will be subjected to Short Portable Mental Status Questionnaire one day before surgery and 1 day after surgery.

  6. Incidence of Post-Operative Cognitive Dysfunction in oncologic surgery (breast, urolgic and general surgery) patients detected with Confusion Assessment Method (CAM)

    Discover Post-Operative Cognitive Dysfunction analyzing changes with Confusion Assessment method (CAM). Worse neurocongitive outcome with lower scores.

    Time frame: Patients will be subjected to Confusion Assessment Method (CAM) within 1 hour from awakening from anesthesia.

  7. Incidence of Emergence Delirium in oncologic surgery (breast, urolgic and general surgery) patients detected with 4AT test

    Discover Post-Operative Cognitive Dysfunction analyzing acute changes in postoperative congition function utilizing the 4AT test. Worse neurocognitve outcome with higher scores. Worse neurocognitve outcome with higher scores

    Time frame: Patients will be subjected to 4 AT test within 1 day from awakening from anesthesia .

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2019 (actual). Primary completion is estimated for Nov 2027, 100 months after the start.

Of 180 non-industry observational studies under Emergence Delirium, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 100 months is above that.

Counting every sponsor, half of 180 studies reached it within 21 months; a quarter within 10 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2018
First posted
Dec 13, 2018
StartActual
Jul 3, 2019
Primary completionEst.
Nov 30, 2027
CompletionEst.
Dec 31, 2027
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
Sex FEMALE→ALL
Oct 16, 2026
Primary outcomes
6 edited, 1 added
What changed in the outcomes
  • EditedIncidence of Post-Operative Cognitive Dysfunction in oncologic surgery (breast-, urolgic and general surgery) patients detected with Montreal Cognitive Assessment testGlobal Examination of Mental Test (GEMS)Time frame: Patients will be subjected to Global Examination of Mental Test (GEMS) test one day before surgery and 1 day after surgery.
  • EditedIncidence of Post-Operative Cognitive Dysfunction in oncologic surgery (breast-, urolgic and general surgery) patients detected with Trail Making Test A and BMinimental State Examination (MMSE)Time frame: Patients will be subjected to Trail Making Test (TMT) A and B one day before surgery and 1day after surgery. → Patients will be subjected to Minimental State Examination (MMSE) test one day before surgery and 1 day after surgery.
  • EditedIncidence of Post-Operative Delirium in breast-oncologic surgery (breast, urolgic and general surgery) patientsTime frame: Patients will be subjected to Confusion Assessment Method (CAM) within 1 hour from awakening from anesthesia .
  • EditedIncidence of Post-Operative Cognitive Dysfunction in breast-oncologic surgery (breast, urolgic and general surgery) patients detected with Trail Making Test A and BTime frame: Patients will be subjected to Short Portable Mental Status Questionnaire one day before surgery and 1 day after surgery. → Patients will be subjected to Trail Making Test (TMT) A and B one day before surgery and 1day after surgery.
  • EditedIncidence of Post-Operative Cognitive Dysfunction in breast-oncologic surgery (breast, urolgic and general surgery) patients detected with MiniMental State Evaluation testTime frame: Patients will be subjected to Confusion Assessment Method (CAM) within 1 hour from awakening from anesthesia. → Patients will be subjected to Short Portable Mental Status Questionnaire one day before surgery and 1 day after surgery.
  • EditedIncidence of Emergence Delirium in oncologic surgery (breast-, urolgic and general surgery) patients detected with 4AT testTime frame: Patients will be subjected to 4 AT test within 1 day from awakening from anesthesia .
  • AddedIncidence of Post-Operative Cognitive Dysfunction in oncologic surgery (breast, urolgic and general surgery) patients detected with Confusion Assessment Method (CAM)Time frame: Patients will be subjected to Confusion Assessment Method (CAM) within 1 hour from awakening from anesthesia.
Oct 16, 2026
Title
Post Operative Cognitive Dysfunction After BreastOncologic Surgery
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Eligibility Sex FEMALE→ALL
    Primary outcomes 6 edited, 1 added
    What changed in the outcomes
    • EditedIncidence of Post-Operative Cognitive Dysfunction in oncologic surgery (breast-, urolgic and general surgery) patients detected with Montreal Cognitive Assessment testGlobal Examination of Mental Test (GEMS)Time frame: Patients will be subjected to Global Examination of Mental Test (GEMS) test one day before surgery and 1 day after surgery.
    • EditedIncidence of Post-Operative Cognitive Dysfunction in oncologic surgery (breast-, urolgic and general surgery) patients detected with Trail Making Test A and BMinimental State Examination (MMSE)Time frame: Patients will be subjected to Trail Making Test (TMT) A and B one day before surgery and 1day after surgery. → Patients will be subjected to Minimental State Examination (MMSE) test one day before surgery and 1 day after surgery.
    • EditedIncidence of Post-Operative Delirium in breast-oncologic surgery (breast, urolgic and general surgery) patientsTime frame: Patients will be subjected to Confusion Assessment Method (CAM) within 1 hour from awakening from anesthesia .
    • EditedIncidence of Post-Operative Cognitive Dysfunction in breast-oncologic surgery (breast, urolgic and general surgery) patients detected with Trail Making Test A and BTime frame: Patients will be subjected to Short Portable Mental Status Questionnaire one day before surgery and 1 day after surgery. → Patients will be subjected to Trail Making Test (TMT) A and B one day before surgery and 1day after surgery.
    • EditedIncidence of Post-Operative Cognitive Dysfunction in breast-oncologic surgery (breast, urolgic and general surgery) patients detected with MiniMental State Evaluation testTime frame: Patients will be subjected to Confusion Assessment Method (CAM) within 1 hour from awakening from anesthesia. → Patients will be subjected to Short Portable Mental Status Questionnaire one day before surgery and 1 day after surgery.
    • EditedIncidence of Emergence Delirium in oncologic surgery (breast-, urolgic and general surgery) patients detected with 4AT testTime frame: Patients will be subjected to 4 AT test within 1 day from awakening from anesthesia .
    • AddedIncidence of Post-Operative Cognitive Dysfunction in oncologic surgery (breast, urolgic and general surgery) patients detected with Confusion Assessment Method (CAM)Time frame: Patients will be subjected to Confusion Assessment Method (CAM) within 1 hour from awakening from anesthesia.
    Title Post Operative Cognitive Dysfunction After BreastOncologic Surgery
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT03774420
Responsible party
Federico Linassi (MD, Principal Investigator, University of Padova) — Principal investigator
First posted
Dec 13, 2018
Start date
Jul 3, 2019
Primary completion
Nov 30, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Oct 16, 2026

Study contacts

Federico Linassi, MD
Contact
federico.linassi@studenti.unipd.it
049 8754256
Federico Linassi, MD
principal investigator · University of Padova

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion